SCNI — Scinai Immunotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.60m
- $5.86m
- $1.31m
Annual cashflow statement for Scinai Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | 10-K | 20-F | 20-F | 20-F |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.4 | -5.8 | -6.5 | 4.8 | -8.31 |
| Depreciation | |||||
| Non-Cash Items | 7.41 | -2.3 | 1.54 | -12.8 | 0.695 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.36 | 0.271 | -4.94 | 0.019 | 0.16 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -7.58 | -7.26 | -9.38 | -6.33 | -6.03 |
| Capital Expenditures | -0.133 | -0.836 | -0.637 | -0.012 | -0.024 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.021 | — | — | — | — |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.112 | -0.836 | -0.637 | -0.012 | -0.024 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 21 | 6.78 | 1.09 | 3.44 | 5.77 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.8 | -3.3 | -9.21 | -2.92 | -0.284 |